Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNOT7 | Q9UIV1 | 3/20 | 0.54 |
| ▸ | PARN | O95453 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 4/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993196 | 0.99 | CNOT7 (0.53) | CNOT7PARNBRD4GRIN1GRIN2B | |
| SCHEMBL13861874 | 0.87 | CNOT7 (0.70) | CNOT7PARNBRD4ADORA2AADORA2B | |
| SCHEMBL7397785 | 0.86 | GRIN1 (0.53) | CNOT7PARNBRD4GRIN1GRIN2B | |
| SCHEMBL14327687 | 0.86 | CNOT7 (0.53) | CNOT7PARNADORA2BMAPTMEN1 | |
| SCHEMBL7443281 | 0.82 | CNOT7 (0.46) | CNOT7PARNADORA2AMEN1KMT2A | |
| SCHEMBL3621012 | 0.81 | CNOT7 (0.57) | CNOT7PARNMEN1KMT2ACYP11B2 | |
| SCHEMBL18024115 | 0.81 | GRIN1 (0.52) | CNOT7PARNGRIN1GRIN2BKMT2A | |
| SCHEMBL10812168 | 0.79 | PDE4A (0.53) | CNOT7PARNBRD4ADORA2AADORA2B | |
| SCHEMBL15293652 | 0.79 | CNOT7 (0.52) | CNOT7PARNBRD4MAPTMEN1 | |
| SCHEMBL27394380 | 0.78 | GDA (0.48) | CNOT7PARNBRD4MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786301-B2 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof | SCHERING CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786301-B2 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof | SCHERING CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786301-B2 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof | SCHERING CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-7312223-B2 | 8-Amino-7-phenylmethyl-1-ethyl-3,7-dihydro-3-(2-hydroxyethyl)-purine-2,6-dione derivatives; urogenital, respiratory system, kidney, cardiovascular, autoimmune or brain disorders; angina pectoris, hypertension, restenosis; anticarcinogenic, hypoglycemic, antiischemic, and hypotensive agents; diabetes | SCHERING CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312223-B2 | 8-Amino-7-phenylmethyl-1-ethyl-3,7-dihydro-3-(2-hydroxyethyl)-purine-2,6-dione derivatives; urogenital, respiratory system, kidney, cardiovascular, autoimmune or brain disorders; angina pectoris, hypertension, restenosis; anticarcinogenic, hypoglycemic, antiischemic, and hypotensive agents; diabetes | SCHERING CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1509525-B9 | PROCESS FOR PREPARING XANTHINE PHOSPHODIESTERASE V INHIBITORS AND PRECURSORS THEREOF | SCHERING CORP (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7192962-B2 | Xanthine phosphodiesterase V inhibitor polymorphs | SCHERING CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192962-B2 | Xanthine phosphodiesterase V inhibitor polymorphs | SCHERING CORPORATION (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1719772-A1 | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof | SCHERING CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20060205943-A1 | Process for preparing xanthine phosphodiesterase V inhibitors and precursers thereof | SCHERING CORPORATION | 2006-09-14 | — | — | US | disclosed |
| EP-1509525-B1 | PROCESS FOR PREPARING XANTHINE PHOSPHODIESTERASE V INHIBITORS AND PRECURSORS THEREOF | SCHERING CORP (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7074923-B2 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof | SCHERING CORPORATION (US) | 2006-07-11 | — | — | US | disclosed |
| US-20030232987-A1 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof | SCHERING CORPORATION | 2003-12-18 | — | — | US | disclosed |
| WO-2003101991-A1 | XANTHINE PHOSPHODIESTERASE V INHIBITOR POLYMORPHS | SCHERING CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003101992-A1 | PROCESS FOR PREPARING XANTHINE PHOSPHODIESTERASE V INHIBITORS AND PRECURSORS THEREOF | SCHERING CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232987-A1 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof | PDE7A, PDE5A, PDE4B | CNOT7 1265/4885PARN 2124/4885BRD4 2498/4885 |
| US-20060205943-A1 | Process for preparing xanthine phosphodiesterase V inhibitors and precursers thereof | PDE7A, PDE4B, PDE5A | CNOT7 1542/4885PARN 1889/4885BRD4 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.